US Bancorp
BCRX icon

US Bancorp’s BioCryst Pharmaceuticals BCRX Stock Holding History

US Bancorp’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54K Buy
154
+23
+18% +$208 ﹤0.01% 3916
2026
Q1 		$1.25K Buy
+131
New +$1.02K ﹤0.01% 3895
2025
Q3 		– Sell
-271
Closed -$2.43K – 4035
2025
Q2 		$2.43K Buy
+271
New +$2.52K ﹤0.01% 3829
2025
Q1 		– Sell
-210
Closed -$1.58K – 4204
2024
Q4 		$1.58K Buy
+210
New +$1.59K ﹤0.01% 3897
2023
Q2 		– Sell
-1,126
Closed -$9.39K – 3999
2023
Q1 		$9.39K Buy
1,126
+1,042
+1,240% +$10K ﹤0.01% 3306
2022
Q4 		$964 Sell
84
-27
-24% -$337 ﹤0.01% 3929
2022
Q3 		$1K Buy
111
+27
+32% +$347 ﹤0.01% 3916
2022
Q2 		$1K Sell
84
-12,016
-99% -$124K ﹤0.01% 3928
2022
Q1 		$197K Buy
12,100
+500
+4% +$8.02K ﹤0.01% 1952
2021
Q4 		$161K Buy
11,600
+3,006
+35% +$39.8K ﹤0.01% 2063
2021
Q3 		$123K Buy
8,594
+194
+2% +$3.06K ﹤0.01% 2192
2021
Q2 		$133K Sell
8,400
-3,000
-26% -$40.8K ﹤0.01% 2152
2021
Q1 		$116K Buy
11,400
+9,400
+470% +$96.9K ﹤0.01% 2191
2020
Q4 		$15K Buy
+2,000
New +$10.3K ﹤0.01% 3016
2020
Q3 		– Sell
-1,000
Closed -$5K – 3713
2020
Q2 		$5K Buy
+1,000
New +$3.99K ﹤0.01% 3293
2019
Q4 		– Sell
-4,648
Closed -$13K – 3650
2019
Q3 		$13K Hold
4,648
– – ﹤0.01% 2977
2019
Q2 		$18K Buy
4,648
+4,302
+1,243% +$25.9K ﹤0.01% 2914
2019
Q1 		$3K Buy
+346
New +$2.96K ﹤0.01% 3332
2015
Q2 		– Sell
-384
Closed -$3K – 3562
2015
Q1 		$3K Hold
384
– – ﹤0.01% 3373
2014
Q4 		$5K Hold
384
– – ﹤0.01% 3262
2014
Q3 		$4K Buy
+384
New +$4.71K ﹤0.01% 3253

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

US Bancorp's BCRX Position: Q2 2026 in Review

US Bancorp increased its BioCryst Pharmaceuticals (BCRX) stake by 18% in Q2 2026, buying an estimated $208 and bringing the position to 154 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3916.

US Bancorp first reported a position in BCRX in Q3 2014 and has held it in 21 quarters since. The position peaked at $197K in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • US Bancorp held 154 shares of BioCryst Pharmaceuticals worth $1.54K as of Q2 2026.
  • US Bancorp bought 23 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $208.
  • BioCryst Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3916 holding.
  • US Bancorp first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 21 quarters since.
  • US Bancorp's BioCryst Pharmaceuticals position peaked at $197K in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.